-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes
Original Research
(2229) Views (412) Full article downloads
Authors: Hironori Masuko, Tohru Sakamoto, Shiko Kaneko, et al
Published Date March 2011
Volume 2011:6 Pages 181 - 189
DOI: http://dx.doi.org/10.2147/COPD.S16383
Hironori Masuko1, Tohru Sakamoto1, Yoshiko Kaneko1, Hiroaki Iijima2, Takashi Naito2, Emiko Noguchi3, Tomomitsu Hirota4, Mayumi Tamari4, Nobuyuki Hizawa1
1Division of Respiratory Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan; 2Tsukuba Medical Center, Ibaraki, Japan; 3Department of Medical Genetics, Majors of Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; 4Laboratory for Respiratory Diseases, Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan
Abstract: Few studies have investigated the significance of decreased FEV1 in non-COPD, nonasthmatic healthy subjects. We hypothesized that a lower FEV1 in these subjects is a potential marker of an increased susceptibility to obstructive lung disease such as asthma and COPD. This was a cross-sectional analysis of 1505 Japanese adults. We divided the population of healthy adults with no respiratory diseases whose FEV1/FVC ratio was ≥70% (n = 1369) into 2 groups according to their prebronchodilator FEV1 (% predicted) measurements:<80% (n = 217) and ≥80% (n = 1152). We compared clinical data – including gender, age, smoking habits, total IgE levels, and annual decline of FEV1 – between these 2 groups. In addition, as our group recently found that TSLP variants are associated with asthma and reduced lung function, we assessed whether TSLP single nucleotide polymorphisms (SNPs) were associated with baseline lung function in non-COPD, nonasthmatic healthy subjects (n = 1368). Although about half of the subjects with lower FEV1 had never smoked, smoking was the main risk factor for the decreased FEV1 in non-COPD, nonasthmatic subjects. However, the subjects with lower FEV1 had a significantly higher annual decline in FEV1 independent of smoking status. Airflow obstruction was associated with increased levels of total serum IgE (P = 0.029) and with 2 functional TSLP SNPs (corrected P = 0.027–0.058 for FEV1% predicted, corrected P = 0.015–0.033 for FEV1/FVC). This study highlights the importance of early recognition of a decreased FEV1 in healthy subjects without evident pulmonary diseases because it predicts a rapid decline in FEV1 irrespective of smoking status. Our series of studies identified TSLP variants as a potential susceptibility locus to asthma and to lower lung function in non-COPD, nonasthmatic healthy subjects, which may support the contention that genetic determinants of lung function influence susceptibility to asthma.
Keywords: airflow obstruction, asthma, chronic obstructive pulmonary disease, pulmonary function test, thymic stromal lymphopoietin
Readers of this article also read:
New therapeutic options in the management of COPD – focus on roflumilast
Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease
Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians
Lung injury after cigarette smoking is particle related
Hypoxemia in patients with COPD: cause, effects, and disease progression
Long-acting ß-adrenoceptor agonists in the management of COPD: focus on indacaterol
Improved patient outcome with smoking cessation: when is it too late?
A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology
Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




